Aims: High mobility group box 1 (HMGB1) is a chromatin structural protein, expressed ubiquitously in the nuclei of mammalian cells. When transported extracellularly, it acts as a tumour suppressor and oncogenic protein. In malignant pleural mesothelioma (MPM), high serum levels of HMGB1 have been related to a poor prognosis. Conversely, the significance of HMGB1 expression in MPM tissues is still unclear. Methods and results: Biopsy samples from 170 patients with MPM were assessed by immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) to evaluate HMGB1 protein and gene expression. The expression level of HMGB1 protein was scored using a semiquantitative system that sums the intensity (0-3) and the percentage (from 0 to 4) of positively stained cells in nuclei, cytoplasm and in both. The final score was considered as high (>3) or low (<3) expression. Gene expression levels were calculated using the DDC t method. High expression levels of HMGB1 as total (P = 0.0011) and cytoplasmic score (P = 0.0462) were related to a worse disease-specific survival (DSS) in the entire cohort and in the clinicopathological subgroups. No significant correlation was found between HMGB1 gene expression and DSS. Conclusions: These findings indicate that HMGB1 may be a useful prognostic biomarker in MPM when detected by immunohistochemistry. Conversely, as it is also expressed in normal and reactive mesothelial cells, HMGB1 cannot be considered a diagnostic biomarker in histological samples of mesothelioma.
Introduction
Malignant mesothelioma is a rare and aggressive tumour arising from the neoplastic transformation of mesothelial cells lining the pleural and peritoneal cavities or, less commonly, the pericardium. 1, 2 Malignant pleural mesothelioma (MPM) accounts for approximately 70% of all mesotheliomas. 3 Causal relationships with exposure to asbestos or asbestoslike mineral fibres have been established for some time, 4 although other potential carcinogenic agents include infection by Simian virus 40, radiation exposure 5 and germline BRCA1-associated protein 1 (BAP1) mutations. 6 The estimated annual incidence of MPM in Europe (15-33 cases per million inhabitants) is expected to increase further during the next 20 years, because of the long latency between exposure to risk factors and disease development. 7 The definite diagnosis of MPM is based on the histological and immunohistochemical evaluation of pleural biopsies. 8 Patients with MPM have a poor prognosis, with a median survival ranging from 8 to 12 months. 9 The gold standard of treatment is a combination of platinum and pemetrexed, extending the patients' survival, on average, by only 12 weeks. 10 The European Organisation for Research and Treatment of Cancer has established that the main predictors of a negative prognosis are a poor performance status (PS), high white blood cell counts, male gender, nonepithelioid subtype, anaemia and thrombocytosis. 11 However, unlike other solid tumours, there are as yet no specific tissue biomarkers with a prognostic significance useful in clinical practice.
High mobility group box 1 (HMGB1) is a highly conserved nuclear protein, which has been implicated in several important biological processes such as transcription, DNA repair, differentiation, development and extracellular signalling. 12, 13 The nuclear role of HMGB1 is to induce bends in DNA, promoting the assembly of several regulatory protein complexes at their cognate binding sites in chromatin.
14 In addition to its nuclear role, HMGB1 can be released into the extracellular environment from necrotic cells and is secreted by activated inflammatory cells, then functioning as an extracellular signalling molecule. 15 HMGB1 exerts crucial functions in inflammation and carcinogenesis through its membrane receptors, involved in activating different pathways. 16, 17 The increased expression of HMGB1 stimulates a variety of processes involved in cancer progression, predicting poor survival in a range of tumour types such as breast carcinoma, 18 colorectal cancer, 19 nasopharyngeal carcinoma, 20 gastric cancer 21 and squamous cell carcinoma of the head and neck. 22 More recently, Yang et al. reported that HMGB1 release from asbestos-induced human mesothelial cells which underwent necrosis is a critical initial step into the mesothelioma carcinogenesis. 23 Another study revealed that HMGB1 is expressed highly and secreted by malignant mesothelioma cells, establishing an autocrine circuit that supports their malignant phenotype. 24 These findings suggest an important role of HMGB1 in the development and progression of mesothelioma, at least in preclinical studies. In addition, patients with peritoneal and pleural mesothelioma showed higher serum levels of HMGB1 compared with the controls, suggesting that this protein may be a useful diagnostic and prognostic biomarker of malignant mesothelioma. 25, 26 However, well-powered studies evaluating the prognostic significance of HMGB1 in tissue samples of MPM are, to the best of our knowledge, still lacking. In this work, we evaluated both protein expression and mRNA levels of HMGB1 by means of immunohistochemistry and reverse transcription-polymerase chain reaction (RT-PCR) from a large series of histological samples of MPM to investigate its potential role as a novel prognostic biomarker.
Materials and methods

T U M O U R S A M P L E S A N D I M M U N O H I S T O C H E M I S T R Y
The study included biopsy samples from 170 patients with definite diagnosis of MPM from April 2005 to December 2014. All the samples were collected by means of video-assisted thoracoscopy performed at the Thoracic Surgery Unit at 'Maggiore della Carit a' Hospital of Novara (Italy). For comparison, eight biopsies of normal mesothelium sampled at the time of bullectomy in patients with pneumothorax and six biopsies of reactive mesothelium from patients with pleurisy were also examined. Informed consent was obtained from all patients before surgery, and this investigation was approved by the Research Ethics Committee of 'Maggiore della Carit a' Hospital of Novara. Tumour and control samples were fixed immediately in formalin for 24 h, embedded in paraffin and processed routinely for histology and immunohistochemistry. The diagnosis of MPM was based on standard histological and immunohistochemistry criteria. 8 All the tumour samples were classified according to the World Health Organisation classification of pleural tumours (Travis et al., 2015), 2 staged clinically and pathologically based on the tumour-node-metastasis (TNM) staging system. 27 The patients' performance status (PS) at the time of diagnosis was graded using the Eastern Cooperative Oncology Group (ECOG) scale. 28 Haematoxylin and eosin (H&E)-stained slides of the pleural biopsies/tumour fragments were reviewed by a pathologist (R.B.) to select a representative area with more than 50% of tumour cells.
Immunohistochemistry analysis was performed in 170 MPM tissues. The 3-lm-thick sections were baked for 1 h at 65°C, deparaffinised with xylene and rehydrated. Antigen retrieval was performed in heated citrate buffer for 30 min at 650 W in a microwave oven. HMGB1 immunostaining process was carried out on a Dako Autostainer (Dako, Carpinteria, CA, USA) by incubating slides with a rabbit polyclonal HMGB1 antibody (diluted at 1:500, clone ab18256; Abcam, Cambridge, UK). The reaction was revealed with the Envision dual rabbit/mouse detection system purchased by Dako (Carpinteria, CA, USA). Normal liver parenchyma and reactive lymph nodes were selected as positive controls.
The expression of HMGB1 in MPMs was scored using the semiquantitative system derived from Soumaoro et al. 29 for both the percentage of positive cells and the staining intensity. The staining extent was scored as 0 (<1%), 1 (1-25%), 2 (26-50%), 3 (51-74%) and 4 (≥75%), according to the percentage of the positive staining, whereas the staining intensity was evaluated as follows: no staining (score = 0), weak staining detectable above background (score = 1), moderate staining (score = 2) and intense staining (score = 3). The final index was obtained by the sum of the intensity and percentage scores for each subgroup, ranging from 0 to 7. The localisation of HMGB1 immunostaining was evaluated according to the system proposed by Koo et al. 30 In particular, we considered the nuclear (N), cytoplasmic (C) and total staining (mean N+C) of the tumour cells, and we then applied the semiquantitative scoring system described above. For the purpose of statistical evaluation, samples with a final staining score of >3 were considered as high expression of HMGB1, whereas samples with a final score of 0-3 were considered as low expression. Each sample was scored independently by two pathologists (R.B., L.B.). If an inconsistency occurred, slides were reviewed jointly by two pathologists to reach a consensus.
The tumour area was macrodissected manually from formalin-fixed paraffin-embedded (FFPE) tissue blocks and 5-lm-thick sections were collected in a 1.5 ml tube for the RNA extraction process. RNA was isolated by using the RecoverAll Total Nucleic Acid Isolation Kit (Life Technologies, Carlsbad, CA, USA), following the manufacturer's instructions. A total of 100 ng of mRNA per sample were reverse-transcribed to cDNA by TaKaRa PrimeScript Samples were amplified by the ABI 7500 real-time PCR machine (Applied Biosystems) under the following thermal profile: initial incubation at 95°C for 20 s, 40 cycles of denaturation at 95°C for 15 s followed by annealing and extension at 60°C for 30 s. Assay results were normalised to rRNA Eucaryotic 18S rRNA Endogenous Control (Life Technologies) and gene expression quantification was performed by the DDC t method, 31 comparing tumour samples with a pool of normal pleura obtained from pneumothorax samples.
S T A T I S T I C A L A N A L Y S I S
Disease-specific survival (DSS) was defined as the time from diagnosis to death or until April 2017, the date of last follow-up for surviving patients. Survival analyses were undertaken using the Kaplan-Meier method and curves were compared by the log-rank test. The association between immunohistochemistry (IHC) staining score or mRNA levels and the clinicopathological characteristics of the patients were analysed, respectively, by v 2 test. The correlation between HMGB1 gene expression and HMGB1 protein expression by IHC was analysed by Pearson's test. All the statistical analyses were performed using STATA version 11 (Stata Corp. LLC, College Station, TX, USA) and software GraphPad Prism, version 7.03 (La Jolla, CA, USA). The level of significance was set at P = 0.05.
Results
P A T I E N T S A N D C L I N I C O P A T H O L O G I C A L F I N D I N G S
The main demographic and clinicopathological findings of the patients included in the study are summarised in Table 1 ; 118 patients were male (69.4%) and the patients' mean age at diagnosis was 68.5 AE 10 years (range = À27 to À91, median 70). Follow-up data after surgery were obtained from all the patients. At the end of the study, six patients (3.53%) were alive with a median follow-up of 56 months (range = 27-94 months). The mean DSS of the cohort was 16 months (range = 1-94 months).
H M G B 1 P R O T E I N E X P R E S S I O N B Y I M M U N O H I S T O C H E M I S T R Y
High mobility group box 1 immunostaining was found in 158 cases (93%) of MPM. In all the positive samples there were tumour cells stained in the nucleus or in the cytoplasm only, mixed with tumour cells stained in both nuclei and cytoplasms (Figure 1) . Conversely, HMGB1 immunostaining was found in the nuclei of the normal pleura ( Figure 1A Table S1 ). The score of nuclear staining was low in 43 cases (25.29%) ( Figure 1C ,D) and high in 127 (74.71%) ( Figure 1E-H) , whereas the total HMGB1 score (Supporting information, Figure S1 ) was low in 69 cases (40.59%) ( Figure 1C,D) and high in 101 (59.41%) (Figure 1E-H 
The correlation between nuclear, cytoplasmic and total score of HMGB1 expression and clinicopathological variables of MPM was examined by v 2 test. As shown in Table 2 , nuclear HMGB1 expression was correlated significantly with asbestos exposure (P = 0.0001), whereas cytoplasmic HMGB1 expression showed a significant correlation only with DSS (P = 0.0295). Interestingly, total HMGB1 expression was correlated significantly with gender (P < 0.0001), tumour clinical stage (P = 0.0049), ECOG score (P = 0.0342) and DSS (P = 0.0036) ( Table 2) . No significant correlation was found between total HMGB1 expression and age, asbestos exposure, other previous malignancies, smoking status, histological subtype (Supporting information, Figure S2 ) and treatment.
C O R R E L A T I O N B E T W E E N
The HMGB1 gene expression analysis was achieved successfully in 110 cases (67.4%); tumour tissue was exhausted in the remaining cases due to the use for standard diagnostic and immunohistochemistry procedures. The median of the relative expression level of the HMGB1 gene [(RQ) value = 1.7] was used as cut-off value to discriminate the patients into high-(RQ ≥ 1.7; score = 1; 55 patients, 32.35%) and low-expression groups (RQ < 1.7; score = 0; 55 patients, 32.35%). Furthermore, the correlation between the gene expression levels of HMGB1 and the clinicopathological variables of patients was investigated. As shown in Table 2 , high expression levels of HMGB1 were correlated positively with ECOG score and treatment.
C O R R E L A T I O N B E T W E E N H M G B 1 S C O R E B Y I M M U N O H I S T O C H E M I S T R Y A N D D S S
We investigated the relationship between the total score of HMGB1 and the DSS by means of Kaplan- Meier analysis. Patients with a high total score had significantly worse DSS than patients with a low total score (P = 0.0011) (Figure 2A ). We then analysed the relationship between the cytoplasmic HMGB1 score and DSS: patients with high scores had worse DSS than patients with low HMGB1 scores (P = 0.0462) ( Figure 2B ). Conversely, the expression levels of nuclear HMGB1 score did not show any statistically significant correlation with DSS (P = 0.5167) ( Figure 2C ). Moreover, we investigated the prognostic value of HMGB1 expression in clinicopathological subgroups of patients with MPM, divided by age (≤68 versus >68), clinical stages (I-II versus III-IV), previous history of other malignancies (not versus yes), histological subtype (epithelioid versus non-epithelioid), ECOG score (0-2 versus >2) and treatment (untreated versus treated with chemotherapy). High levels of total score of HMGB1 expression was correlated with worse DSS in the subgroups of patients treated by chemotherapy (P = 0.0097) (Figure 2D ) and untreated (P = 0.0006) ( Figure 2E ) in the subgroups of patients with epithelioid (P = 0.0039) ( Figure 2F ) and non-epithelioid subtypes (P = 0.0035) ( Figure 2G ) in patients older than 68 years (P = 0.0014) (data not shown) and in patients with no previous history of other malignancies (P = 0.0008).
Interestingly, high levels of cytoplasmic HMGB1 expression were associated with worse DSS in untreated patients (P = 0.0167) (data not shown) and in the subgroup of patients with non-epithelioid (P = 0.0058) mesothelioma, whereas nuclear scores of HMGB1 showed no correlation with DSS in any of the subgroups analysed. The correlation between HMGB1 gene expression and DSS was also investigated. The Kaplan-Meier survival curves generated for the low-and high-expression groups of patients indicated that there was no significant difference (P = 0.77) in terms of DSS between the two groups ( Figure 2H ).
C O R R E L A T I O N B E T W E E N H M G B 1 G E N E E X P R E S S I O N A N D H M G B 1 S C O R I N G B Y I M M U N O H I S T O C H E M I S T R Y
Finally, we analysed the statistical correlation between the HMGB1 gene expression and IHC scoring in the cohort of 110 MPM cases by means of Pearson's test, which correlates the log fold-change values for mRNA and IHC score. No statistically significant correlation was found between the HMGB1 gene expression and IHC scoring, evaluated in terms of total score (Figure 3C ), nuclear score ( Figure 3B ), cytoplasmic score ( Figure 3A) , percentage of nuclear positivity (Figure 3D) , intensity of nuclear positivity ( Figure 3F ), percentage of cytoplasmic positivity ( Figure 3E ) and intensity of cytoplasmic positivity ( Figure 3G ).
U N I V A R I A T E A N D M U L T I V A R I A T E A N A L Y S I S
The variables associated putatively with DSS were analysed individually with a univariate Cox proportional hazards regression model (Table 3 ). Significant variables in the univariate analysis were added to a multivariate model. As shown in Table 3 , clinical stages (I-II versus III-IV), histological subtype (epithelioid versus non-epithelioid), treatment type (treated versus untreated) and, interestingly, total HMGB1 score continued as significant prognostic factors.
Discussion
Malignant pleural mesothelioma is an extremely aggressive tumour: the average disease-specific survival after histological diagnosis is currently 8-12 months, with a slight improvement in patients treated with chemotherapy. 10, 32 According to the Cancer and Leukaemia Group and the European Organisation for Research and Treatment of Cancer, poor performance status (PS greater than 2), nonepithelioid histology, advanced clinical stages (III and IV) and the patients' age older than 75 years were identified as poor prognostic factors. 33 Moreover, there have been several reports concerning several serum biomarkers potentially useful in predicting the prognosis of MPM, such as mesothelin, 34 osteopontin 35 and fibulin-3. 36 In addition, Tabata et al. also reported that high serum levels of HMGB1 were related to poor prognosis, suggesting its use in clinical management of MPM. 26 However, unlike other malignant tumours, tissue biomarkers detectable by immunohistochemistry or by molecular biology techniques able to predict the prognosis of MPM are still lacking. A recent meta-analysis by Wu et al. 37 indicated that the overexpression of HMGB1, when detected by immunohistochemistry, is associated significantly with poor overall survival and progressionfree survival in several types of malignant tumours, such as gastric cancer, colorectal cancer, hepatocellular carcinoma, pancreatic cancer, nasopharyngeal carcinoma, head and neck squamous cell carcinoma, oesophageal cancer and gynaecological tumours. In addition, Jube et al. 24 found a statistically significant correlation between tumour stage and HMGB1 expression levels in the cytoplasm of mesothelioma cells. However, their results were obtained in a small cohort of the patients and need more powerful studies before being confirmed definitively. On these bases, the main goals of our study were to: (i) assess if the Log-rank test, P = 0.0011
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In this work, we demonstrated that high expression levels of HMGB1, evaluated by immunohistochemistry, in cancer cells of clinical samples of MPM were correlated significantly with a worse DSS. This result was obtained either when the score was calculated as total score (nuclear plus cytoplasmic) and cytoplasmic score alone, in the entire cohort or in the clinical and pathological subgroups of patients. Conversely, the expression levels of nuclear HMGB1 score alone did not show any statistically significant correlation with DSS. HMGB1 is a nuclear protein expressed constitutively in both cancer and normal cells and acts as a chromatin-binding factor that bends DNA, promoting access to several transcriptional proteins. 38 Some studies have demonstrated that HMGB1 could be shuttled actively between the nucleus and the cytoplasm of tumour cells. 39 Following various stressors (e.g. cytokine, chemokine, heat, hypoxia, H 2 O 2 ), HMGB1 translocates from the nucleus to the cytoplasm, where it functions as a positive regulator of autophagy. 40 At the extracellular level, HMGB1 functions as a cytokine during inflammation, cell differentiation and cell migration, and also seems to play a role in tumour metastasis development. 41, 42 Because, in our study, the cytoplasmic but not nuclear overexpression of HMGB1 was associated significantly with poor prognosis, we can speculate that in malignant mesothelioma cells, under stress environmental stimuli, HMGB1 migrates from the nucleus Kaplan-Meier curves of disease-specific survival (DSS) for malignant pleural mesothelioma (MPM) patients. Patients with high total scores had significantly worse DSS than patients with low total scores (P = 0.0011) (A); patients with high cytoplasmic scores had worse DSS than patients with low cytoplasmic scores (P = 0.0462) (B), whereas the expression analysis of nuclear score did not show any statistically significant correlation with DSS (P = 0.5167) (C). Patients with high total scores of high mobility group box 1 (HMGB1) had a significantly worse DSS in the subgroups of patients treated with chemotherapy (P = 0.0097) (D) and untreated (P = 0.0006) (E) with epithelioid subtype (P = 0.0039) (F) and non-epithelioid subtypes (P = 0.0035) (G). In patients evaluated for HMGB1 gene expression, no differences in terms of DSS were identified in low-versus high-expression groups (P = 0.718) (H).
to the cytoplasm of the tumour cells, and after secretion into the extracellular matrix it enhances tumour cell survival and proliferation through several cancerogenic mechanisms. 43 Furthermore, Jube et al. 24 demonstrated, by means of in-vivo and in-vitro experiments, that MPM cells expressed HMGB1 strongly and secreted it at high levels, establishing an autocrine circuit that promotes the HMGB1-secreting MPM cell proliferation and survival.
Our study did not show any statistically significant correlation with DSS when the detection method of RT-PCR was used. Moreover, no statistically significant correlation was found between the HMGB1 gene expression and HMGB1 immunohistochemistry scoring. These results were similar to the findings reported by Ueda et al. 44 in colorectal cancers, and could be explained tentatively by the presence of inflammatory cells, also expressing HMGB1, mixed with cancer cells in tissues used for the evaluation of HMGB1 gene expression. Alternatively, posttranscriptional regulation of HMGB1 mRNA or posttranslational modifications of the protein itself could contribute to explain this discrepancy. [45] [46] [47] Indeed, Napolitano et al. reported that the different isoforms of HMGB1 (hyperacetylated and non-acetylated) are responsible for the protein release from mesothelioma cells into the extracellular compartment and therefore not detectable by immunohistochemistry. 48 In conclusion, we have demonstrated that the expression levels of HMGB1 are correlated inversely with DSS in MPM cases when assessed by immunohistochemistry. To the best of our knowledge, this study represents the most significant analysis in terms of the number of patients studied, and suggests the possible use of HMGB1 as new prognostic tissue biomarker in the clinical management of patients with MPM. However, as HMGB1 is also expressed in normal and reactive mesothelial cells, it cannot be used as a diagnostic biomarker in MPM. 
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